Cytokinetics Inc header image

Cytokinetics Inc

CYTK

Equity

ISIN null / Valor 21533074

NASDAQ (2026-04-24)
USD 65.32-0.24%

Cytokinetics Inc
UMushroom community rating:

star star star star star
4.33 3 votes No rating yet
NegativeNeutralPositive

About company

Cytokinetics Inc. is a biopharmaceutical company with a specialized focus on the development of innovative therapies aimed at enhancing muscle function for individuals suffering from debilitating diseases where muscle performance is compromised. Established over 25 years ago in South San Francisco, California, the company has carved a niche in muscle biology, pioneering the discovery, development, and commercialization of muscle activators and inhibitors. These novel therapeutic agents are designed as potential treatments for a range of serious conditions affecting muscle health. Under the leadership of experienced industry professionals, Cytokinetics has made significant strides in scientific research, evidenced by its extensive portfolio of over 115 scientific publications, participation in more than 100 clinical trials, and the securing of numerous patents. The company's commitment to advancing muscle biology research extends to its active engagement with the healthcare and scientific communities through peer-reviewed journals and medical forums, aiming to contribute meaningfully to patient care and medical knowledge.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

62.0%1Y
70.5%3Y
147%5Y

Performance

57.0%1Y
64.9%3Y
63.7%5Y

Volatility

Market cap

8045 M

Market cap (USD)

Daily traded volume (Shares)

967,139

Daily traded volume (Shares)

1 day high/low

47.775 / 46.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.33

3 votes
Performance:
starstarstarstarstar
4.33
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.33
Nature:
starstarstarstarstar
4.33
Joaquim Silva
United Kingdom, 05 Nov 2025
star star star star star
gains
Duarte *****
United Kingdom, 25 Oct 2025
star star star star star
-
Duarte *****
United Kingdom, 21 Oct 2025
star star star star star
Positive

EQUITIES OF THE SAME SECTOR

Netflix Inc
Netflix Inc Netflix Inc Valor: 1413346
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.41%USD 92.44
NVIDIA Corp
NVIDIA Corp NVIDIA Corp Valor: 994529
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%USD 208.27
Advanced Micro Devices Inc
Advanced Micro Devices Inc Advanced Micro Devices Inc Valor: 903491
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
13.91%USD 347.81
Alphabet Inc
Alphabet Inc Alphabet Inc Valor: 29798545
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.35%USD 342.32
SK hynix Inc
SK hynix Inc SK hynix Inc Valor: 18382960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.38%EUR 744.00
Brady Corp
Brady Corp Brady Corp Valor: 913942
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.69%USD 80.70
Marvell Technology Inc
Marvell Technology Inc Marvell Technology Inc Valor: 111229262
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%USD 164.31
CDW Corporation
CDW Corporation CDW Corporation Valor: 21034308
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.84%USD 135.32
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc Biomarin Pharmaceutical Inc Valor: 729021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.48%USD 53.18
Kura Oncology Inc
Kura Oncology Inc Kura Oncology Inc Valor: 28160920
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.11%USD 9.26